Abstract. Purpose: To investigate the in vitro binding properties of a novel radiolabelled bombesin analogue, 177 Lu-AMBA, in human neoplastic and non-neoplastic tissues selected for their expression of the bombesin receptor subtypes GRP-R, NMB-R and BRS-3. Methods: In vitro receptor autoradiography was performed in cancers expressing the various bombesin receptor subtypes. The novel radioligand 
I-[D-Tyr
6 ,β-Ala 11 , Phe 13 ,Nle 14 ]-bombesin (6) (7) (8) (9) (10) (11) (12) (13) (14) . In vitro incidence of detection of each of the three bombesin receptor subtypes was evaluated in each tumour.
Results:
Introduction Peptide hormones and their receptors not only are very important physiological regulators but also are becoming increasingly relevant in tumour management: many malignant human tumours overexpress various peptide hormone receptors, which can be used for in vivo tumour targeting [1] . For instance, the high expression of somatostatin receptors in gastroenteropancreatic neuroendocrine tumours allows highly effective somatostatin receptor targeted tumour imaging and therapy using radiolabelled somatostatin analogues [2] [3] [4] .
Recently, other peptides and their receptors have attracted increasing interest, such as cholecystokinin, neurotensin and bombesin receptors [1] . Bombesin receptors are of particular interest, since widely occurring tumours such as prostate and breast cancers often express bombesin receptors [5, 6] . Moreover, it has also been reported that radiolabelled bombesin analogues can successfully image these tumours in vivo [7, 8] . Finally, a large number of suitable radiopharmaceuticals have been synthesised and characterised for this purpose [9] [10] [11] . One of the most recent and most extensively characterised radiopharmaceuticals of this type is 177 Lu-AMBA [12] . The unlabelled AMBA (DO3A-CH 2 CO-G-4-aminobenzoyl-Q-W-A-V-G-H-L-M-NH 2 ) binds with high affinity to gastrin-releasing peptide (GRP) and neuromedin B (NMB) receptors, while it has no affinity for BRS-3 receptors [12] . It has an excellent pharmacokinetic profile [12] and has been found to inhibit tumour growth in PC3 tumour-bearing mice [12] . This compound is presently in phase I clinical trials.
The aim of the present study was to investigate the in vitro binding characteristics of the novel radiolabelled bombesin analogue 177 Lu-AMBA, using a selection of human tissues expressing the various bombesin receptors. The method used for this purpose was bombesin receptor autoradiography, as described previously [13] . The results, using ]-bombesin (6) (7) (8) (9) (10) (11) (12) (13) (14) , in the same tissues. The investigated tissues were human cancers expressing GRP-R (also named BB 2 ), NMB-R (also named BB 1 ) or BRS-3 (also named bb 3 ), non-neoplastic tissues including normal pancreas and colon, and chronic pancreatitis. The results of this study should permit identification of the most suitable tumour targets for clinical trials with this radiopharmaceutical. The data may also facilitate the interpretation of whole-body 177 Lu-AMBA scans with regard to the labelling of normal, non-neoplastic tissues.
Materials and methods
In vitro receptor autoradiography was performed in selected cancers and non-neoplastic tissues tested in previous studies for their bombesin receptor expression. They are listed in Table 1 . Cryostat sections (20 μM) of the tissue samples were prepared. Several radioligands were used in parallel in these experiments. The radioligand tested was 177 Lu-AMBA, radiolabelled by Bracco, Inc. [12] (Princeton, NJ) and shipped to Switzerland. All experiments with this radioligand were performed within 1 week after labelling. For comparison, receptor autoradiography was also performed with other bombesin radioligands, such as 125 I-Tyr 4 -bombesin, known to preferentially label GRP receptors [14] , and the newly developed radioligand ]-bombesin (6) (7) (8) (9) (10) (11) (12) (13) (14) , which has been reported to be an outstanding universal ligand that identifies all bombesin receptor subtypes [13, 15] .
For autoradiography, tissue sections were mounted on precleaned microscope slides and stored at −20°C for at least 3 days to improve adhesion of the tissue to the slide. The sections were first pre-incubated in 10 mM HEPES (pH 7.4) for 5 min at room temperature. They were then incubated in 10 mM HEPES, 130 mM NaCl, 4.7 mM KCI, 5 mM MgCl 2 , 1 mM ethylene glycol-bis (β-aminoethylether)-N-N′-tetraacetic acid, 0.1% BSA, 100 μg/ml bacitracin (pH 7.4) and one of the radioligands for 1 h at room temperature. 177 Lu-AMBA (1.5 Ci/μmol) was added at a concentration of 100 pM in the presence or absence of 0.05 μM AMBA. ]-bombesin (6) (7) (8) (9) (10) (11) (12) (13) (14) , GRP or NMB. This protocol has been shown to discriminate adequately between the three receptor subtypes GRP-R, NMB-R and BRS-3 [13, 16] . After incubation, the sections were washed four times for 2 min each in 10 mM HEPES with 0.1% Results Table 1 summarises the results. Prostatic, mammary and renal cell carcinomas, as well as the gastrointestinal stromal tumours (GIST), all identified as GRP-R-expressing tumours with established bombesin radioligands, were very well detected with in vitro receptor autoradiography using 177 Lu-AMBA. Some of the tumours with low levels of GRP-R could still be identified with 177 Lu-AMBA, while they were not detected with ]-bombesin(6-14) (Table 1) , reflecting a slightly better sensitivity of the 177 Lu-AMBA tracer, probably owing to its higher affinity and/or its different radioisotope.
All tumours that had been identified as NMB-Rexpressing tumours with established radioligands were also visualised with 177 Lu-AMBA. Conversely, none of the BRS-3-expressing tumours were detected with 177 Lu-AMBA. By way of example, Fig. 1a shows a GRP-R- expressing prostate cancer labelled similarly with the universal ligand and with 177 Lu-AMBA, Fig. 1b shows an NMB-R-expressing ileal carcinoid identified with both tracers and Fig. 1c shows a BRS-3-positive bronchial carcinoid strongly labelled with the universal radioligand but not with 177 Lu-AMBA. As the tested cases were all preselected and chosen as receptor positive in the majority of cases or as negative controls in a few selected cases, one should not draw any conclusions about the natural incidence of receptor expression in the various types of tumour listed in Table 1 . Figure 2 shows that the normal human pancreas, known to be devoid of GRP-R, is not labelled with 177 Lu-AMBA, whereas the GRP-R-expressing mouse pancreas is strongly labelled with 177 Lu-AMBA under identical experimental conditions. Moreover, the islets of the human pancreas, known to express BRS-3, were labelled with the universal tracer Lu-AMBA (Fig. 3) . Finally, GRP-R were detected in human pancreatic tissues that are pathologically altered (chronic pancreatitis), indicating that GRP-R, when present in this human tissue, can be identified under the experimental conditions chosen in this study. In fact, 177 Lu-AMBA appears to identify these GRP-R in chronic pancreatitis with greater sensitivity than does 125 I-Tyr 4 -bombesin, as illustrated in Fig. 3 .
While none of the pancreatic cancers had measurable amounts of GRP-R with either tracer, a few colon carcinomas showed a low density of heterogeneously distributed GRP-R measured either with 177 Lu-AMBA or with standard tracers (Table 1) . It should further be noted that the smooth muscles of the colon express GRP-R in vitro, in quantities reaching the density level of many GRP-R-expressing tumours; these muscular receptors were detected either with 177 Lu-AMBA or with the established bombesin ligands. Figure 4 shows two complete displacement curves for 177 Lu-AMBA in the presence of various bombesin-like compounds in a GRP-R and an NMB-R-expressing tumour, illustrating the expected rank order of potency of analogues for the respective receptor.
Discussion
We showed in a previous report that 175 Lu-AMBA has a very high affinity for human GRP and NMB receptors (IC 50 : 0.8 and 0.9 nM, respectively) expressed in human tissues while it has only low affinity for BRS-3 receptors (IC 50 : >1,000 nM) [12] . These experiments were performed with 175 Lu-AMBA as displacer. In the present study, we used the 177 Lu-labelled AMBA as radiotracer, which corresponds exactly to the tracer that may be used in future for nuclear medicine purposes in vivo in humans. We can herewith markedly extend the preliminary data reported previously [12] : All GRP-Rexpressing human cancers were very strongly labelled with 177 Lu-AMBA. The same was true for all NMB-R-positive tumours. Conversely, tumours with BRS-3 receptors were not visualised. The sensitivity of 177 Lu-AMBA appears slightly better than that of 125 I-Tyr 4 -bombesin or the 125 Ilabelled universal bombesin analogue, although a direct comparison cannot be made owing to the different radioisotopes present in the two radiopharmaceuticals. It is to be noted that a few tumours expressing a low density of GRP-R could be readily identified with 177 Lu-AMBA while they remained negative with 125 I-Tyr 4 -bombesin. Of further interest is the fact that GRP-R-positive peritumoural vessels were readily identified with 177 Lu-AMBA as well as with standard tracers. The present study therefore strongly suggests that 177 Lu-AMBA will be a targeting tool for GRP-R-expressing tumour cells and for neoangiogenic vessels simultaneously.
The binding characteristics of 177 Lu-AMBA could also be confirmed in non-neoplastic tissues. While the mouse pancreas, as control, was shown to express a very high density of GRP-R, the normal human pancreatic acini were 177 Lu-AMBA in a GRP-Rexpressing prostatic cancer (upper graph) and an NMB-R-expressing ileal carcinoid (lower graph). Displacement by AMBA ( • ), GRP (▲) and NMB (■). Rank order of potencies of compounds corresponds to the expressed bombesin receptor subtype devoid of measurable amounts of GRP-R [17] . However, in conditions of chronic pancreatitis, GRP-R could be identified in acini, as reported previously [17] , again with a better sensitivity when using 177 Lu-AMBA than when using 125 I-Tyr 4 -bombesin. Conversely, as expected, the BRS-3-expressing islets were not detected with 177 Lu-AMBA, while these same islets were strongly labelled with the universal ligand [17] . It should be stressed that the normal pancreas is a very rapidly degradable tissue; it is hardly possible to exclude degradation of proteins, including receptor proteins, in particular in the human pancreas, which may be resected under suboptimal conditions. Nevertheless, that the human pancreas data are truly negative data is indicated not only by the positive control of the mouse pancreas tested under similar experimental conditions but also by the strong labelling of BRS-3 receptors in the islets of the human pancreas, which represents a positive control for the quality of the investigated human pancreas. While a minority of colon carcinomas had GRP-R, usually in a very low density and with a heterogeneous distribution, the normal colonic smooth muscles expressed, as reported previously [18] , a high density of GRP-R, all labelled with 177 Lu-AMBA. While the GRP-R density in the smooth muscles was lower than that in prostate cancers and lower than or comparable to that in breast cancers and GIST, it was higher than that in renal cell carcinomas.
This study suggests that 177 Lu-AMBA is an excellent radioligand to target GRP-R and NMB-R-expressing human tumours, such as prostate, mammary and renal cell carcinomas (GRP-R), gastrointestinal stromal tumours (GRP-R) and ileal carcinoids (NMB-R), but also GRP-Rpositive peritumoural vessels. Further, this in vitro study seems to predict the absence of significant receptormediated in vivo uptake in the normal human pancreas (in contrast to very high uptake in the mouse pancreas), while in vivo uptake of 177 Lu-AMBA may be foreseen in chronic pancreatitis and at the level of the colonic smooth muscles, both tissues expressing GRP-R. Based on these promising data, the development of 177 Lu-AMBA for clinical use as a targeting agent may open exciting new opportunities in nuclear medicine.
